2012 Press Release
- Dainippon Sumitomo Pharma and Shionogi Announce the NHI Drug Price Standard Listing and Launch of anti-hypertension drug "AIMIX® Combination Tablets LD/HD"
- Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor "Dolutegravir", Disclosed by ViiV Healthcare
- Financial Results for the Second Quarter of FY2012
- Shionogi Enters into a License and Collaboration Agreement for Its Oral beta-Secretase Inhibitor Program for the Treatment of Alzheimer's Disease with Janssen Pharmaceuticals, Inc.
- Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio
- Ezose Sciences Inc. Press Release: EZOSE SCIENCES FORMS ALLIANCE WITH FAST FORWARDTO DISCOVER BIOMARKERS TO DIAGNOSE MULTIPLE SCLEROSIS
- Shionogi Provides Pirespa® 200mg Tablet to ILDONG PHARMACEUTICAL for the Treatment of Idiopathic Pulmonary Fibrosis in South Korea
- Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
- Shionogi Announces the Conducting of an International Industry-academic Collaboration, SHIONOGI Science Program 2012, and a Drug Discovery Competition, FINDS 2012
- Shionogi and Kotobuki to Enter a License Agreement on KT6-971, a Cholesterol Absorption Inhibitor
- Memorandum Signed with Five Danish Universities for Collaboration in Research and Development
- Antitrichomonal Agent, Flagyl® Approval for Additional Indication for Amoebic Dysentery, Giardiasis, Anaerobic Infection and Infectious Enteritis
- Synthetic Antibacterial Agent, Baktar® Approval for Additional Indication of Prophylaxis and Treatment for Pneumocystis pneumonia
- ILDONG PHARMACEUTICAL Receives a Marketing and Manufacturing Approval for Pirespa® 200mg Tablet
- First Quarter of Fiscal Year 2012 Conference Call
- Shionogi Filed a New Drug Application for Recombinant Human Leptin for Lipodystrophy
- Shionogi Launches "Endoxan® Powder 100mg for Oral" for Nephrotic Syndrome
- Shionogi Files an Application for an Anti-hypertension Drug "S-474474", a Combination of Irbesartan and Trichlormethiazide
- Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naive Adults with HIV-1
- Shionogi to Determine the Contents of Stock Options as Compensation (Stock Acquisition Rights)
- Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
- Filing Lawsuit against InterMune, Inc.
- Shionogi Limited Press Release: Shionogi Launches New European Headquarters in London
- Shionogi Inc. Press Release: U. S. FOOD AND DRUG ADMINISTRATION ACCEPTS SHIONOGIfS OSPEMIFENE NEW DRUG APPLICATION IN VULVAR AND VAGINAL ATROPHY
- Shionogi Announces Personnel Reassignment
- Shionogi to Issue of Stock Options as Compensation (Stock Acquisition Rights) to Members of Board of Directors
- Ezose Sciences Inc. Press Release:EZOSE SCIENCES ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER
- Angiotensin Converting Enzyme Inhibitor, Longes® Approval for Additional Indication of Appropriate Dose and Dose Regimen of Child at Age 6 or Over
- Shionogi Announces Initial Data from Phase IIb study of S-555739, Prostaglandin D2 Receptor Antagonist
- Dainippon Sumitomo Pharma and Shionogi to Sign a License Agreementfor the Co-marketing of "DSP-8153", Combination Product of Anti-hypertension Drugs irbesartan and amlodipine besilate
- Shionogi Launches Injectable Analgesics for Cancer Pain, "OxiFast® Injection 10mg" and "OxiFast® Injection 50mg"
- Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic,"Finibax® 0.25g/0.5g for Intravenous Drip Infusion" and "Finibax® 0.25g Kit for Intravenous Drip Infusion"
- Shionogi Files a New Drug Application for Ospemifene Oral Tablets 60mg for the Treatment of Vulvar and Vaginal Atrophy
- Shionogi Inc. News Release: SHIONOGI FILES A NEW DRUG APPLICATION FOR OSPEMIFENE ORAL TABLETS 60MG FOR THE TREATMENT OF VULVAR AND VAGINAL ATROPHY
- Ezose Sciences Inc. Press Release:EZOSE SCIENCES AND HIROSAKI UNIVERSITY TO COLLABORATE IN GLYCOMICS RESEARCH TO FIND NEW CANCER BIOMARKERS
- Ezose Sciences Inc. Press Release: EZOSE SCIENCES AND SIGMA-TAU ADVANCE PROJECTS IN GLYCOMICS
- Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV
- Shionogi Enters into Exclusive Licensing Agreement with OncoTherapy Science to Develop and Market Cancer Peptide Vaccines
- Anticancer Agent, Ifomide®, Approval of Additional Indication of Malignant Lymphoma
- Antitrichomonal Agent, Flagyl®, Approval for Additional Indication of Bacterial Vaginosis
- Shionogi Announces Appointment of Directors and Corporate Officers
- Shionogi Establishes a Developmental Subsidiary in EU
- Shionogi Inc. Press Release: STUDY DATA SHOW CUVPOSA® REDUCED CHRONIC SEVERE DROOLING IN PATIENTS AGES 3-16 YEARS-OLD WITH NEUROLOGIC CONDITIONS
- Shionogi Receives Approval of Injectable Analgesics for Cancer Pain, "OxiFast® Injection 10mg" and "OxiFast® Injection 50mg"